The estimated Net Worth of Robert E. Jr Brown is at least $1.63 million dollars as of 16 May 2019. Mr. Brown owns over 2,209 units of ANI Pharmaceuticals Inc stock worth over $1,225,514 and over the last 11 years he sold ANIP stock worth over $0. In addition, he makes $403,654 as Independent Director at ANI Pharmaceuticals Inc.
Robert has made over 2 trades of the ANI Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 2,209 units of ANIP stock worth $45,130 on 16 May 2019.
The largest trade he's ever made was exercising 5,458 units of ANI Pharmaceuticals Inc stock on 15 November 2016 worth over $96,880. On average, Robert trades about 639 units every 76 days since 2013. As of 16 May 2019 he still owns at least 22,561 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Mr. Brown stock trades at the bottom of the page.
Robert E. Brown Jr. serves as Independent Director of the Company. Mr. Brown has been active in the venture capital and private equity business for over 30 years and has been the sole stockholder, director and President of MVP Management Company since 2000. MVP Management Company conducts business as MVP Capital Partners (“MVP Capital”), and is the investment management company for Meridian Venture Partners II, L.P. (“MVP II”), a mid-sized venture capital and private equity firm focused on expansion capital and microcap buyout investments. Mr. Brown is the Managing Partner of MVP II and the President and sole stockholder and sole director of Meridian Venture Partners II Co., the corporate general partner of the general partner of MVP II. Mr. Brown co-founded MVP II in 2000 and its predecessor fund, Meridian Venture Partners, in 1987. Prior to 1987, Mr. Brown was a principal in a merchant banking firm active in both private equity and investment banking. Mr. Brown began his professional career as a certified public accountant with Arthur Andersen & Co. Subsequently, he worked for a subsidiary of The Penn Central Corporation as a financial analyst, and after graduating from law school, practiced corporate tax law at the firm of Morgan, Lewis & Bockius in Philadelphia. In his role at MVP Capital, Mr. Brown has served on the boards of numerous privately-held companies, including several companies in the healthcare industry such as Implex Corporation, Dorland Data Networks, Omega Health Systems, Air Medical Group Holdings, Comprehensive Addiction Programs, Inc., and MCMC Holdings LLC. Mr. Brown holds an A.B. degree from Princeton University, an M.B.A. from the Wharton School of the University of Pennsylvania, and a J.D. from the University of Pennsylvania Law School.
As the Independent Director of ANI Pharmaceuticals Inc, the total compensation of Robert Brown at ANI Pharmaceuticals Inc is $403,654. There are 4 executives at ANI Pharmaceuticals Inc getting paid more, with Robert Schrepfer having the highest compensation of $2,160,980.
Robert Brown is 69, he's been the Independent Director of ANI Pharmaceuticals Inc since 2020. There are 1 older and 13 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O ANI PHARMAECUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... et Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: